Fusion Pharmaceuticals Inc. Revenue
Fusion Pharmaceuticals Inc. reported Revenue of $2.07 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-20.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2024-05-07
- Fusion Pharmaceuticals Inc. revenues for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Fusion Pharmaceuticals Inc. revenues for the quarter ending 2023-09-30 was $2.01M, a 1108.43% increase year-over-year.
- Fusion Pharmaceuticals Inc. revenues for the quarter ending 2023-06-30 was $34.00K, a 94.04% decline year-over-year.
- Fusion Pharmaceuticals Inc. revenues for the quarter ending 2023-03-31 was $28.00K, a 95.21% decline year-over-year.
- Fusion Pharmaceuticals Inc. revenues for fiscal 2023 was $2.07M, a 41.55% increase from fiscal 2022.
- Fusion Pharmaceuticals Inc. revenues for fiscal 2022 was $1.46M, a 1.46% increase from fiscal 2021.
- Fusion Pharmaceuticals Inc. revenues for fiscal 2021 was $1.44M.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $2.01M derived: sum of 2 quarters · filed 2024-03-20 | $2.04M derived: sum of 3 quarters · filed 2024-03-20 | $2.07M 10-K · filed 2024-03-20 |
| 2023-09-30 | $2.01M 10-Q · filed 2023-11-07 | $2.04M derived: sum of 2 quarters · filed 2023-11-07 | $2.07M 10-Q · filed 2023-11-07 | $2.21M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-06-30 | $34.00K 10-Q · filed 2023-08-08 | $62.00K 10-Q · filed 2023-08-08 | $202.00K derived: sum of 3 quarters · filed 2024-05-07 | $368.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-03-31 | $28.00K 10-Q · filed 2024-05-07 | $168.00K derived: sum of 2 quarters · filed 2024-05-07 | $334.00K derived: sum of 3 quarters · filed 2024-05-07 | $904.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $306.00K derived: sum of 2 quarters · filed 2024-03-20 | $876.00K derived: sum of 3 quarters · filed 2024-03-20 | $1.46M 10-K · filed 2024-03-20 |
| 2022-09-30 | $166.00K 10-Q · filed 2023-11-07 | $736.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.32M 10-Q · filed 2023-11-07 | $1.92M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $570.00K 10-Q · filed 2023-08-08 | $1.16M 10-Q · filed 2023-08-08 | $1.75M derived: sum of 3 quarters · filed 2023-08-08 | $2.07M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $585.00K 10-Q · filed 2023-05-11 | $1.18M derived: sum of 2 quarters · filed 2023-05-11 | $1.50M derived: sum of 3 quarters · filed 2023-05-11 | $2.02M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $594.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $919.00K derived: sum of 2 quarters · filed 2023-03-16 | $1.44M derived: sum of 3 quarters · filed 2023-03-16 | $1.44M 10-K · filed 2023-03-16 |
| 2021-09-30 | $325.00K 10-Q · filed 2022-11-08 | $846.00K derived: sum of 2 quarters · filed 2022-11-08 | $846.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $521.00K 10-Q · filed 2022-08-09 | $521.00K 10-Q · filed 2022-08-09 |